×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AZN – astrazeneca plc ordinary shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AZN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/27
07:00 am
azn
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Low
Report
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
3/20
01:31 am
azn
Astrazeneca (AZN) was upgraded by Wall Street Zen from "hold" to "buy"
Low
Report
Astrazeneca (AZN) was upgraded by Wall Street Zen from "hold" to "buy"
3/18
02:07 pm
azn
Astrazeneca (AZN) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
Astrazeneca (AZN) had its "buy" rating reaffirmed by TD Cowen.
3/15
05:59 pm
azn
AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment [Yahoo! Finance]
Low
Report
AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment [Yahoo! Finance]
3/12
06:11 pm
azn
Astrazeneca (AZN) is now covered by Weiss Ratings. They set a "buy (b)" rating on the stock.
Low
Report
Astrazeneca (AZN) is now covered by Weiss Ratings. They set a "buy (b)" rating on the stock.
3/12
09:24 am
azn
Astrazeneca (AZN) was downgraded by Wall Street Zen from "buy" to "hol
Low
Report
Astrazeneca (AZN) was downgraded by Wall Street Zen from "buy" to "hol
3/10
08:30 am
azn
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
Low
Report
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
3/9
07:00 am
azn
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Medium
Report
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/27
08:05 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 27
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 27
3/20
08:00 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 20
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 20
3/19
07:52 pm
azn
Form 3 ASTRAZENECA PLC For: Mar 18 Filed by: Sharma Mani
Low
Report
Form 3 ASTRAZENECA PLC For: Mar 18 Filed by: Sharma Mani
3/16
08:46 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 16
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 16
3/10
08:08 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 10
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 10
3/10
07:38 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 10
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 10
3/6
08:12 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 06
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 06
3/6
07:51 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 06
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 06
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
AstraZeneca's combo lung cancer treatment fails late-stage study main goal [Reuters (UK)]
8.3%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
TOP News Decliners
3/7
Amarin Stock Looks Like a Heart-Healthy Buy on the Dip [Yahoo! Finance News]
-4.1%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: